4OXC
Crystal structure of XIAP BIR1 domain
4OXC の概要
| エントリーDOI | 10.2210/pdb4oxc/pdb | 
| 関連するPDBエントリー | 4MTZ | 
| 分子名称 | E3 ubiquitin-protein ligase XIAP, ZINC ION (3 entities in total) | 
| 機能のキーワード | xiap, bir, zn finger, ligase | 
| 由来する生物種 | Homo sapiens (Human) | 
| 細胞内の位置 | Cytoplasm: P98170 | 
| タンパク質・核酸の鎖数 | 4 | 
| 化学式量合計 | 49692.58 | 
| 構造登録者 | |
| 主引用文献 | Cossu, F.,Milani, M.,Grassi, S.,Malvezzi, F.,Corti, A.,Bolognesi, M.,Mastrangelo, E. NF023 binding to XIAP-BIR1: Searching drugs for regulation of the NF-kappa B pathway. Proteins, 83:612-620, 2015 Cited by  PubMed Abstract: Inhibitor of Apoptosis Proteins (IAPs) are the target of extensive research in the field of cancer therapy since they regulate apoptosis and cell survival. Smac-mimetics, the most promising IAP-targeting compounds specifically recognize the IAP-BIR3 domain and promote apoptosis, competing with caspases for IAP binding. Furthermore, Smac-mimetics interfere with the NF-κB survival pathway, inducing cIAP1 and cIAP2 degradation through an auto-ubiquitination process. It has been shown that the XIAP-BIR1 (X-BIR1) domain is involved in the interaction with TAB1, an upstream adaptor for TAK1 kinase activation, which in turn couples with the NF-κB survival pathway. Preventing X-BIR1 dimerization abolishes XIAP-mediated NF-κB activation, thus implicating a proximity-induced mechanism for TAK1 activation. In this context, in a systematic search for a molecule capable of impairing X-BIR1/TAB1 assembly, we identified the compound NF023. Here we report the crystal structure of the human X-BIR1 domain in the absence and in the presence of NF023, as a starting concept for the design of novel BIR1-specific compounds acting synergistically with existing pro-apoptotic drugs in cancer therapy.PubMed: 25619915 DOI: 10.1002/prot.24766 主引用文献が同じPDBエントリー | 
| 実験手法 | X-RAY DIFFRACTION (2.9 Å) | 
構造検証レポート
検証レポート(詳細版) をダウンロード
をダウンロード
 をダウンロード
をダウンロード










